F2, coagulation factor II, thrombin, 2147

N. diseases: 490; N. variants: 42
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 GeneticVariation disease BEFREE At first TACE, patients with TN-HCC showed a significantly lower proportion of male gender (74.9% vs. 84.3%), higher proportion of liver cirrhosis (61.9% vs. 49.3%), higher aspartate aminotransferase (median 48 vs. 31 IU/L), alanine aminotransferase (median 38 vs. 26 IU/L), alpha-fetoprotein (AFP) (median 96.6 vs. 7.7 ng/mL), and total bilirubin (mean 1.0 vs. 0.8 mg/dL) levels, longer prothrombin time (median 1.05 vs. 1.01 international normalized ratio), higher tumor number (mean 2.1 vs. 1.7), larger tumor size (median 3.1 vs. 1.6 cm), and lower proportion of Barcelona Clinic Liver Cancer stage 0-A (55.6% vs. 71.9%) than patients with R-HCC (all P < 0.05). 31187326 2019
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 GeneticVariation disease BEFREE The risk of rebleeds was higher in the presence of multiple lesions (OR 4.2, 95% CI 1.1-16.2 and 3.8, 95% CI 1.3-11.3 and 8.6, 95% CI 1.4-52.6), liver cirrhosis (OR 4.0, 95% 1.1-15.0) and prothrombin time < 30% (OR 4.2, 95% 1.1-15.4) with a moderate effect size. 31190204 2019
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 30298976 2019
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE We aimed to validate the functional fibrinogen thromboelastography assay (FF-TEG) and propose a new model to estimate fibrinogen levels via the Clauss method (Clauss) using data from a prothrombin time-derived fibrinogen assay (PT-Fg) in patients with liver cirrhosis. 30418134 2019
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 GeneticVariation disease BEFREE In multivariate analyses, liver cirrhosis was identified as an independent risk factor associated with post-ERCP bleeding (<i>p</i>=0.003) after further adjustment for prothrombin time, antiplatelet/coagulant, duration of ERCP, and stent insertion. 31016905 2019
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE Our study aimed to externally validate the ability of the prothrombin time-international normalized ratio to albumin ratio (PTAR), an objective and simple scoring system, to predict 90-day mortality in critically ill patients with cirrhosis. 30601338 2019
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE Based on these observations, the Study Group proposed the following diagnostic criteria for ACLF in Japan: patients with cirrhosis and a Child-Pugh score of 5-9 should be diagnosed as having ACLF when a deterioration of liver function (serum bilirubin level ≥5.0 mg/dL and prothrombin time value ≤40% of the standardized values and/or international normalization rate ≥1.5) caused by severe liver damage develops within 28 days after acute insults, such as alcohol abuse, bacterial infection, gastrointestinal bleeding, or the exacerbation of underlying liver diseases. 29361652 2018
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE In patients with a high prothrombin time-international normalized ratio to albumin ratio, pathologic liver cirrhosis (P < .001), postoperative ascites (P = .039), and postoperative liver failure (P = .040) were greater than for their counterparts. 29754978 2018
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE Recently, the easy Liver Fibrosis Test (eLIFT), a sum of points attributed to age, gender, gamma-glutamyl transpeptidase, aspartate transaminase, platelets, and prothrombin time, was developed for diagnosing advanced fibrosis and cirrhosis in chronic liver disease. 28710435 2017
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis. 28472132 2017
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE The prothrombin time once considered as an isolated measure of bleeding risk was rejected, and cirrhosis shifted from a purely hemorrhagic construct to a mixed and thrombosis-prone paradigm. 27801884 2017
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE This study aimed to develop and evaluate a predictive score, named Platelet count, Alpha fetoprotein (AFP) and Prothrombin-INR (PAP) for the prediction of large oesophageal varices and to compare PAP score with eight common liver fibrosis scores (AAR, APRI, GUCI, BRC score, Fibro-Alfa, FIB4, Lok and Fibro-Q) in patients with hepatitis C virus (HCV) induced liver cirrhosis. 28504002 2017
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 GeneticVariation disease BEFREE Patients with cirrhosis included those with Child-Pugh Grade B (43%), preoperative moderate ascites (100%), a prothrombin time of ≥ 4 s (75%) and greater weight loss. 28520878 2017
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE Our new cirrhosis score (CS) for the assessment of liver cirrhosis, based on a linear combination of ARFI, platelet (PLT), liver surface, and prothrombin index (PI), was calculated by linear discriminant analysis. 28067683 2017
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE After that, aspartate aminotransferase (AST), total bilirubin (TBIL), total bile acid (TBA), prothrombin time (PT), aspartate aminotransferase to platelet ratio index (APRI) and serum HBV DNA were confirmed as independent predictors of significant liver necroinflammation in CHB patients with cirrhosis by univariate analysis and multivariate analysis (p = 0.002, 0.044, 0.001, 0.014, 0.01 and 0.02 respectively). 27615602 2016
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 GeneticVariation disease BEFREE In this case-control study, we investigated the frequency of Janus kinase 2 (JAK2) (JAK2 V617F), Factor V Leiden (FVL G1691A), and Prothrombin (G20210A) mutations in cirrhotic patients with PVT (LCi+/PVT+ group, n = 21) in comparison with two control collectives (cirrhotic patients without PVT, LCi+/PVT- group, n = 43; PVT patients without liver cirrhosis, LCi-/PVT+ group, n = 29). 25115839 2015
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 GeneticVariation disease BEFREE The thrombophilic genetic factors (THRGFs), PAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q and Prothrombin 20210A, were studied as risk factors in 865 Caucasian patients with liver cirrhosis, consecutively enrolled from June 2008 to January 2014. 25987440 2015
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE These data show that low chemerin in patients with more severe liver cirrhosis is associated with reduced Quick prothrombin time. 25595667 2015
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE Multivariable analysis identified alcohol consumption (odds ratio (OR) 6.4, 95% CI 1.3-30.1), aspartate aminotransferase >0.5 times the upper limit of normal (OR 15.4, 95% CI 1.9-122.6), and prothrombin time (OR 12.0, 95% CI 1.2-120.4), but not HBV DNA or quantitative HBsAg level, to be independent predictors of the presence of cirrhosis. 25449247 2014
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 GeneticVariation disease BEFREE The prevalence of the FVL and prothrombin G20210A mutations were compared between patients with Budd-Chiari syndrome or PVT without cirrhosis and healthy individuals (controls) and between patients with cirrhosis, with and without PVT. 24793031 2014
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 GeneticVariation disease BEFREE Decreased serum albumin and prolonged plasma prothrombin time (PT) were showed in LC patients carrying genotype AA. 21779363 2011
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 GeneticVariation disease BEFREE We studied thrombophilic genetic factors (TGFs) MTHFR C677TT, PAI1 4G-4G, V Leiden Q506, prothrombin G20210A as risk factors in 94 patients with HCC with and without portal vein thrombosis (PVT), compared with 214 patients with liver cirrhosis (LC) with and without PVT and 94 healthy controls (HC). 18618228 2009
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 GeneticVariation disease BEFREE Plasma concentrations of factor II, VII, X, V, protein C (PC) total protein S (tPS) antithrombin (AT) and D-dimers (DD) were measured in 13 LC patients with PVT heterozygous for PT G20210A, in 13 LC patients with PVT without PT G20210A and in 13 LC controls matched by age, sex and Child-Pugh score. 16493481 2006
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 GeneticVariation disease BEFREE We have evaluated the prothrombin time, a number of haemostatic variables synthesised by the liver (FII, FV, FVII and activated FVII, AT and fibrinogen) and two polymorphisms of the FVII gene (5'F7 and 353R/Q) in: (a) patients with liver cirrhosis (n=118), (b) patients with chronic hepatitis (n=102) and (c) controls (n=100). 15893284 2005
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.400 Biomarker disease BEFREE Multivariate analysis identified baseline serum bilirubin >/=6 mg/dL (odds ratio [OR]: 5.61; 95% confidence interval [CI]: 1.66-21.61; P = 0.018), pre-existing cirrhosis (OR: 4.52; 95%CI: 1.26-30.42; P = 0.034), and baseline prothrombin time <40% (OR: 3.75; 95%CI: 1.03-43.86; P = 0.045) as independent determinants of the event. 15740488 2005